Lonsurf (trifluridine/tipiracil) / Otsuka 
Welcome,         Profile    Billing    Logout  
 6 Diseases   125 Trials   125 Trials   2571 News 


«12...22232425262728293031323334»
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
    Rare case of an uterine cervix metastasis from a sigmoid adenocarcinoma () -  Oct 16, 2019 - Abstract #ESGO2019ESGO_941;    
    Further therapy included selective internal radiotherapy and oral therapy with Trifluridine/Tipiracil...Therefore, the colposcopic image in this case is untypical for primary cervical carcinoma. Management should be adjusted according to the tumor origin.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker:  LUPIN: Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Oct 8, 2019   
    P1,  N=94, Active, not recruiting, 
    TAS-102 treatment may be ineffective in patients with a decreased neutrophil count of <25%. Trial completion date: Jan 2020 --> Jun 2020 | Trial primary completion date: Nov 2019 --> Aug 2019
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, sunitinib / Generic mfg.
    Enrollment open, Trial initiation date, Metastases:  SUNRISE-CRC: Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC) (clinicaltrials.gov) -  Oct 1, 2019   
    P2/3,  N=60, Recruiting, 
    The present study can contribute to the determination of the effective dosing interval of TAS-102 and bevacizumab in patients with mCRC and is thought to lead to prophylaxis of neutropenia and prolongation of the treatment period. Not yet recruiting --> Recruiting | Initiation date: Jul 2019 --> Oct 2019
  • ||||||||||  Promising targeted approaches (Helsinki 2) -  Sep 30, 2019 - Abstract #DGHO2019DGHO_1214;    
    The combination of trifluridine/tipiracil (TAS-102) is a new oral anticancer drug with activity in gastrointestinal cancer...Apatinib is a small-molecule tyrosine kinase inhibitor that selectively inhibits the VEGFR-2 tyrosine kinase...The recent results from a large phase 3 trial with andecaliximab, a monoclonal antibody that inhibits matrix-metalloproteinase-9 (MMP-9), failed to replicate the positive data from a previous study of andecaliximab in combination with chemotherapy in untreated HER2-negative gastric or gastroesophageal junction adenocarcinoma...Randomized clinical studies with zolbetuximab are ongoing. Data on new targeted therapy options (excluding immunotherapy) will be discussed.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Phase classification, Combination therapy, Metastases:  TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma (clinicaltrials.gov) -  Sep 27, 2019   
    P1,  N=20, Recruiting, 
    While evidence on optimal sequential treatment from clinical trials is still missing, data from the TKK could provide valuable information on decision making and outcome. Phase classification: P1/2 --> P1
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial primary completion date, PD(L)-1 Biomarker, IO biomarker:  LUPIN: Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Sep 23, 2019   
    P1,  N=94, Active, not recruiting, 
    Since the AC concluded that the most plausible ICER was £49,392 per QALY gained, and that T/T meets end-of-life criteria, T/T was recommended as a cost effective use of NHS resources. Trial primary completion date: Aug 2019 --> Nov 2019
  • ||||||||||  Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal, IO Biomarker:  A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. (Pubmed Central) -  Sep 16, 2019   
    We review the latest clinical data that support the utilization of several targeted agents alone or in combination with backbone chemotherapy across different lines of treatment and patient populations and highlight recommendations for their usage. Recent advances in the treatment landscape are also summarized, including genomic profiling and preliminary results with immune checkpoint inhibitors.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal:  Late-line treatment in metastatic gastric cancer: today and tomorrow. (Pubmed Central) -  Sep 7, 2019   
    A further recently reported study, KEYNOTE-059, which was a single-arm phase II trial of the PD-1 inhibitor pembrolizumab in a mainly non-Asian population, has provided evidence supporting the use of this immunotherapy in patients with advanced GC. As further third-line options become available, more GC patients are expected to benefit from an individualized evidence-based approach to later-line therapy, with a common goal of extending survival and improving outcomes for their refractory disease.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
    Review, Journal:  Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer. (Pubmed Central) -  Sep 7, 2019   
    Adverse events ≥ Grade 3 were most frequently haematological in nature. Thus, trifluridine/tipiracil provides a valuable and much needed treatment option for patients with metastatic gastric or gastroesophageal junction adenocarcinoma that has progressed on at least two prior therapies.
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
    Enrollment open, Combination therapy:  Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE (clinicaltrials.gov) -  Aug 28, 2019   
    P1,  N=57, Recruiting, 
    Furthermore, FTD/TPI is well tolerated and can be considered as a treatment option in elderly patients with mCRC. Not yet recruiting --> Recruiting
  • ||||||||||  paclitaxel / Generic Mfg., Opdivo (nivolumab) / Ono Pharma, BMS
    Journal, MSi-H Biomarker, PARP Biomarker, PD(L)-1 Biomarker, IO Biomarker:  Advances in the treatment of gastric cancer. (Pubmed Central) -  Aug 21, 2019   
    Addition of docetaxel to adjuvant S-1 will likely emerge as a new care standard. Pembrolizumab and nivolumab improve survival and now are treatment options in chemotherapy-refractory gastric cancer, especially for programmed death ligand 1-positive or MSI-high cancers.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs (clinicaltrials.gov) -  Aug 21, 2019   
    P1,  N=33, Recruiting, 
    Pembrolizumab and nivolumab improve survival and now are treatment options in chemotherapy-refractory gastric cancer, especially for programmed death ligand 1-positive or MSI-high cancers. Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2019 --> Aug 2021